MED
Medifast, Inc. (MED) Economic Moat Analysis (2026)
Overall Score
Brand Pricing Power
Gross margin is high at 69.2%, but negative EBIT and net margins indicate limited pricing power translation into durable profits.
Price-to-sales of 0.44x and price-to-book of 0.72x suggest the market is not assigning a premium moat valuation.
Switching Costs Retention
No evidence of meaningful switching costs in the current financials; profitability remains negative despite a healthy revenue base.
Working capital is strong, but there is no clear sign of customer lock-in or recurring revenue durability from the available metrics.
Network Effects
No observable network-effect indicators are present in the financial data.
Returns on capital remain negative, which does not support a self-reinforcing scale advantage.
Cost Advantage
Operating leverage is not yet visible: EBIT margin is -4.4% and ROIC is -7.7%.
Low enterprise value relative to sales may reflect distress rather than a structural cost advantage.
Intangible Assets
R&D intensity is minimal at 0.3% of revenue, offering little evidence of a strong innovation moat.
There is no visible evidence in the metrics of patents, regulatory exclusivity, or other protected intangibles.
Efficient Scale
The company has a solid current ratio of 4.9x and cash ratio of 1.7x, but that liquidity does not itself indicate efficient scale.
Negative returns on assets and invested capital suggest the business is not yet converting scale into durable excess returns.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Medifast, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

